The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

In conclusion, our findings indicate that PD-L1 expression as a predictive biomarker has limitations and that the decision to pursue testing mu st be carefully implemented for clinical decision-making.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research